Last update Sept. 17, 2022

Pizotifen

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Pizotifen is a sedative antihistamine with weak antimuscarinic properties and a potent serotonin and tryptamine antagonist indicated for migraine prophylaxis. It is also used as an appetite stimulant. Oral administration in one to three daily doses.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (very high percentage of protein binding and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Davanzo 2014), especially during the neonatal period and in the event of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Pizotifen is also known as


Pizotifen in other languages or writings:

Group

Pizotifen belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pizotifen in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 78 %
Molecular weight 295 daltons
Protein Binding 90 %
VD 11.9 l/Kg
Tmax 5 hours
23 hours

References

  1. AEMPS. Pizotifeno. Ficha técnica. 2022 Full text (in our servers)
  2. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014 Abstract
  3. Paladin. Pizotifen Drug Summary. 2012 Full text (in our servers)

Total visits

4,479

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM